Patrick Mayeux
Responsable de l'équipe, Hématopoïèse normale et pathologique
Institution:
USPC - SET - SVS
Summary
Published articles Show More
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia
...Published in Cell Reports
AMPK is a master regulator of cellular metabolism that exerts either oncogenic or tumor suppressor activity depending on context. Here, we report that the specific AMPK agonist GSK621 selectively kills acute myeloid leukemia (AML) cells but spares normal hematopoietic progenitors. This differential sensitivity results from a unique synthetic lethal...
Control of Pim2 kinase stability and expression in transformed human haematopoietic cells
...Published in Bioscience Reports
The oncogenic Pim2 kinase is overexpressed in several haematological malignancies, such as multiple myeloma and acute myeloid leukaemia (AML), and constitutes a strong therapeutic target candidate. Like other Pim kinases, Pim2 is constitutively active and is believed to be essentially regulated through its accumulation. We show that in leukaemic ce...
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
...Published in Science Advances
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide short-term disease control, but relapse invariably occurs within months. Pim protein kinases are oncogenic FLT3-ITD targets exp...
Experience
Responsable de l'équipe
université Paris Descartes
Hématopoïèse normale et pathologique; Développement, Reproduction, Cancer (DRC); UMR 8104 / UMR_S1016, Institut Cochin; Faculté de Médecine
